Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures.
OBJECTIVE
Statins are an essential component of the therapeutic approach of patients with atherosclerotic disease. Statin use is also associated with improved peri-operative and long-term outcomes in these patients. We aimed to define the role of statin treatment in patients undergoing percutaneous revascularization procedures.
We searched Medline for studies assessing the effect of statin treatment on percutaneous interventions.
Early statin treatment is associated with improved outcomes in patients undergoing percutaneous coronary intervention procedures. Current evidence implies that statin treatment may also play a beneficial role in the management of patients undergoing percutaneous renal artery revascularization and endovascular abdominal aortic aneurysm repair, carotid angioplasty/stenting and endovascular peripheral arterial interventions.


CONCLUSIONS
Preliminary data suggest that statins exert multiple beneficial actions in patients undergoing percutaneous interventions. Future randomized trials are expected to further evaluate the beneficial effects of statins in these procedures.
Paraskevas
Kosmas I
KI
Department of Clinical Biochemistry (Vascular Disease Prevention Clinic), Royal Free Hospital and Royal Free University College Medical School, London, UK.
Athyros
Vasilios G
VG
Briana
Despina D
DD
Kakafika
Anna I
AI
Karagiannis
Asterios
A
Mikhailidis
Dimitri P
DP
D015906:Angioplasty, Balloon, Coronary / Q000401:mortality; D017544:Aortic Aneurysm, Abdominal / Q000188:drug therapy / Q000601:surgery; D003327:Coronary Disease / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000517:prevention & control; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000601:surgery; D016032:Randomized Controlled Trials as Topic; D012077:Renal Artery / Q000601:surgery; D015607:Stents
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors